Home > Oncology > ASCO GU 2022 > Renal Cell Carcinoma > Nivolumab monotherapy represents an alternative first-line treatment option for treatment-naïve mRCC

Nivolumab monotherapy represents an alternative first-line treatment option for treatment-naïve mRCC

Presented By
Dr Michael Atkins, Georgetown Lombardi Comprehensive Cancer Center, DC, USA
Conference
ASCO GU 2022
Trial
Phase 2, HCRN GU16-260
Results from the phase 2 HCRN GU16-260 trial demonstrated monotherapy with nivolumab to be an effective alternative treatment option for treatment-naïve patients with advanced or metastatic renal cell carcinoma (mRCC). Salvage treatment with nivolumab/ipilimumab for patients who progress on nivolumab monotherapy appeared to be of limited benefit. Nivolumab is approved for patients with VEGFR TKI-resistant RCC and the nivolumab/ipilimumab combination is approved for treatment-naïve patients with IMDC intermediate-risk and poor-risk RCC. Dr Michael Atkins (Georgetown Lombardi Comprehensive Cancer Center, DC, USA) presented the results of the phase 2 HCRN GU16-260 trial (NCT03117309), which evaluated the efficacy and toxicity of nivolumab monotherapy in treatment-naïve RCC as well as the efficacy of nivolumab/ipilimumab salvage in patients with tumours resistan...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on